If that paragraph, you quote bmfjch - gives you any confidence whatsoever, that Vivesto will in fact proceed to a Phase 2 trial, than I am happy for you. (Some 2 years and 4 months after its license from Kazia)
Under its development under Dr Gil Mor from Yale - this drug, then known as TRXE-002 was always considered to have potential to work in a whole range of other cancers. That information is readily available from around 2015 and just before.
Vivesto state in that quarterly report - a cash backing of the equivalent US$11 million. The patients for Cantrixil run out in 2032.
KZA Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
